Published March 25, 2026 | Version Final version
Journal article Open

Memantine: A look ahead. Insights into structure, syntheses, receptor binding mechanisms, drug hybrids and formulations, and potential repurposing

Authors/Creators

  • 1. ROR icon Universidad de Extremadura

Files

Memantine-FINAL-EurJMedChem.pdf

Files (11.5 MB)

Name Size Download all
md5:2ca697cd127370cd402bb730b5c2432e
11.5 MB Preview Download

Additional details

Identifiers

DOI
10.1016/j.ejmech.2026.118791

Related works

Is original form of
Journal article: 10.1016/j.ejmech.2026.118791 (DOI)

Dates

Available
2026-03-25

Software

Repository URL
https://doi.org/10.1016/j.ejmech.2026.118791

References

  • [1] Scheltens, P.; Blennow, K.; Breteler, M. M. B.; de Strooper, B.; Frisoni, G. B.; Salloway, S.; Van der Flier, W. M. Alzheimer's disease. Lancet 2016, 388(10043), 505-517. https://doi.org/10.1016/s0140-6736(15)01124-1. [2] Long, S.; Benoist, C.; Weidner, W. World Alzheimer Report 2023: Reducing dementia risk: never too early, never too late; Alzheimer's Disease International: London, England, 2023. [3] Mullard, A. 2023 FDA approvals. Nat. Rev. Drug Discov. 2024, 23, 88-95. https://doi.org/10.1038/d41573-024-00001-x. [4] Howes, L. Is this a golden age of small-molecule drug discovery? Chem. Eng. News 2023, 101(36), 28-32. [5] Graham, W. V.; Bonito-Oliva, A.; Sakmar, T. P. Update on Alzheimer's disease therapy and prevention strategies. Annu. Rev. Med. 2017, 68, 413-430. https://doi.org/10.1146/annurev-med-042915-103753. [6] Brewster II, J. T.; Dell'Acqua, S.; Thach, D. Q.; Sessler, J. L. Classics in chemical neuroscience: donepezil. ACS Chem. Neurosci. 2019, 10, 155-167. https://doi.org/10.1021/acschemneuro.8b00517. [7] Zhou, Y.; Fu, Y.; Yin, W.; Li, J.; Wang, W.; Bai, F.; Xu, S.; Gong, Q.; Peng, T.; Hong, Y.; Zhang, D.; Zhang, D.; Liu, Q.; Xu, Y.; Xu, H. E.; Zhang, H.; Jiang, H.; Liu, H. Kinetics-driven drug design strategy for next-generation acetylcholinesterase inhibitors to clinical candidate. J. Med. Chem. 2021, 64, 1844-1855. https://doi.org/10.1021/acs.jmedchem.0c01863. [8] Witt, A.; Macdonald, N.; Kirkpatrick, P. Memantine hydrochloride. Nat. Rev. Drug Discov. 2004, 3, 109-110. https://doi.org/10.1038/nrd1411. [9] Liu, J.; Obando, D.; Liao, V.; Lifa, T.; Codd, R. The many faces of the adamantyl group in drug design. Eur. J. Med. Chem. 2011, 46, 1949-1963. https://doi.org/10.1016/j.ejmech.2011.01.047. [10] Wanka, L.; Iqbal, K.; Schreiner, P. R. The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chem. Rev. 2013, 113, 3516-3604. https://doi.org/10.1021/cr100264t. [11] Alam, S.; Lingenfelter, K. S.; Bender, A. M.; Lindsley, C. W. Classics in chemical neuroscience: memantine. ACS Chem. Neurosci. 2017, 8, 1823-1829. https://doi.org/10.1021/acschemneuro.7b00270. [12] Marotta, G.; Basagni, F.; Rosini, M.; Minarini, A. Memantine derivatives as multitarget agents in Alzheimer's disease. Molecules 2020, 25, 4005. https://doi.org/10.3390/molecules25174005. [13] Kumar, V.; Kumar, V.; Kumar, N.; Kumar, V.; Jangid, K. Memantine-based derivatives: synthesis and their biological evaluation. In Natural Product-based Synthetic Drug Molecules in Alzheimer's Disease; Sharma, A., Modi, G. P., eds.; Springer: Singapore, 2023; pp. 185-209. [14] Dane, C.; Montgomery, A. P.; Kassiou, M. The adamantane scaffold: beyond a lipophilic moiety. Eur. J. Med. Chem. 2025, 291, 117592. https://doi.org/10.1016/j.ejmech.2025.117592. [15] Singh, Y. P.; Kumar, H. Recent advances in medicinal chemistry of memantine against Alzheimer's disease. Chem. Biol. Drug Des. 2024, 104, e14638. https://doi.org/10.1111/cbdd.14638. [16] Tari, P. K.; Parsons, C. G.; Collingridge, G. L.; Rammes, G. Memantine: updating a rare success story in pro-cognitive therapeutics. Neuropharmacology 2024, 244, 109737. https://doi.org/10.1016/j.neuropharm.2023.109737. [17] Eliel, E. L.; Wilen, S. H. Stereochemistry of Organic Compounds; John Wiley & Sons, Inc.: New York, 1994, pp. 67, 1204. [18] Hellwich, K.-H.; Siebert, C. D. Stereochemistry Workbook; Springer: Berlin, 2006, p. 166. [19] Mills, J.; Krumkalns, E. Adamantyl secondary amines. Patent US 3391142 A, 1968. [20] Scherm, A.; Hammersbach, D. P. Drugs or medicines for influencing the central nervous system. Patent US 4122193 A, 1978. [21] Punju, B. A.; Nagarajan, P.; Srinivasu, K.; Rajamannar, T. Crystal form II of memantine hydrochloride. Patent WO2005/069742, 2005. [22] Merli, V.; Mantovani, S.; Daverio, P.; Bianchi, S.; Spreafico, A. Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride. Patent WO2006/076562 A1, 2006. [23] Merli, V.; Daverio, P.; Kovacsne-Mezei, A.; Aron-Hime, J. Polymorphs of memantine hydrochloride. Patent WO2006/076560 A1, 2006. [24] Tihi, J.; Meleh, M.; Vrecer, F.; Zupet, R.; Pucelj, J.; Pelko, M. Process for the preparation of memantine and its hydrochloric acid salt form. Patent EP 1908748 A1, 2008. [25] IP.COM Prior Art Database 000159896, 2007. Novel polymorphic form of memantine hydrochloride, process for preparation and pharmaceutical compositions thereof. Available at: https://priorart.ip.com/IPCOM/000159896. [26] Lou, W.-J.; Hu, X.-R.; Gu, J.-M. Memantinium chloride 0.1-hydrate. Acta Cryst. 2009, E65, o2191. https://doi.org/10.1107/s1600536809031791. [27] Tkachev, V. V.; Tkacheva, N. S.; Kazachenko, V. P. Structure of 3,5-dimethyl-1-adamantanamine-2,4,6-triisopropylbenzosulphonate salt in the crystal. J. Struct. Chem. 2017, 58, 615−617. https://doi.org/10.1134/S0022476617030271. [28] Tuksar, M.; Rubčić, M.; Meštrović, E. (3,5-Dimethyladamantan-1-yl)ammonium methanesulfonate (memantinium mesylate): synthesis, structure and solid-state properties. Acta Crystallogr. E Crystallogr. Commun. 2019, E75, 1274-1279. https://doi.org/10.1107/S2056989019009988. [29] Ayudhya, T. I.; Rheingold, A. L.; Dingra, N. N. Crystal structure of memantine−carboxyborane. Acta Cryst. 2019, E75, 543−546. https://doi.org/10.1107/S2056989019004092. [30] Bhardwaj, V.; Shaiwale, M.; Lakhani, B.; Ballabh, A. A series of memantine based salts with various aromatic and aliphatic carboxylic acids: crystallographic analysis, Hirshfeld surfaces and dissolution study. J. Mol. Struct. 2020, 1206, 127672. https://doi.org/10.1016/j.molstruc.2019.127672. [31] Kuang, W.; Liu, J.; Lin, X.; Wu, S.; Gong, J.; Yin, Q.; Wang, J. Insoluble salt of memantine with a unique fluorescence phenomenon. Mol. Pharmaceutics 2022, 19, 1389−1399. https://doi.org/10.1021/acs.molpharmaceut.1c00931. [32] Tuksar, M.; Topić, E.; Rubčić, M.; Meštrović, E. Exploring salts of memantine with inorganic anions: from polymorphism and solid-state transitions to potential for drug formulations. Mol. Pharmaceutics 2024, 21, 4700-4707. https://doi.org/10.1021/acs.molpharmaceut.4c00670. [33] Rani, A.; Khan, J.; Choudhary, L.; Kumar, M.; Jha, A.; Pandey, G.; Nand, B. Unraveling the synthesis and therapeutic potential of FDA-approved Alzheimer's drugs: a comprehensive review. Tetrahedron 2025, 175, 134517. https://doi.org/10.1016/j.tet.2025.134517. [34] Schreiner, P. R.; Wanka, L. Aminoadamantan-derivate, verfahren zur ihrer herstellung und ihre verwendung. Patent WO2006010362 A1 (2006). [35] Wanka, L.; Cabrele, C.; Vanejews, M.; Schreiner, P. R. -Aminoadamantanecarboxylic acids through direct C-H bond amidations. Eur. J. Org. Chem. 2007, 1474-1490. https://doi.org/10.1002/ejoc.200600975. [36] Vu, B. D.; Ba, N. M. H.; Pham, V. H.; Phan, D. C. Simple two-step procedure for the synthesis of memantine hydrochloride from 1,3-dimethyladamantane. ACS Omega 2020, 5, 16085-16088 (Correction: ACS Omega 2020, 5, 26295). https://doi.org/10.1021/acsomega.0c01589. [37] Vu, B. D.; Ba, N. M. H.; Tran, H. V.; Phan, D. C. An improved synthesis of memantine hydrochloride. Org. Prep. Proced. Int. 2020, 52, 463-467. https://doi.org/10.1080/00304948.2020.1785807. [38] Nguyen, T. H. T.; Nguyen, T. D.; Phan, D. C.; Vu, B. D. A concise two-step method for preparation of memantine hydrochloride from 1,3-dimethyladamantane. Int. J. Pharm. Sci. Res. 2021, 12, 6370-6383. https://doi.org/10.13040/IJPSR.0975-8232.12(12).6370-83. [39] Nguyen, T. H. T.; Le, V. D.; Ngo, S. T.; Nguyen, T. H. T.; Phan, D. C., Vu, B. D. Two step cost-saving process for industrial scale production of 1-amino-3,5-dimethyladamantane hydrochloride (an anti-Alzheimer's drug). Asian J. Chem. 2022, 34, 251-255. https://doi.org/10.14233/ajchem.2022.23447. [40] Ivleva, E. A.; Klimochkin, Y. N. Convenient synthesis of memantine hydrochloride. Org. Prep. Proced. Int. 2017, 49, 155-162. https://doi.org/10.1080/00304948.2017.1291004. [41] Bosnidou, A. E.; Muñiz, K. Intermolecular radical Csp3-H amination under iodine catalysis. Angew. Chem. Int. Ed. 2019, 58, 7485-7489. https://doi.org/10.1002/anie.201901673. [42] Iwata, M.; Furiya, Y.; Ishitani, H.; Kobayashi, S. Development of continuous-flow reactions for the synthesis of anti-Alzheimer drug memantine. Chem. Eur. J. 2025, 31, e202403562. https://doi.org/10.1002/chem.202403562. [43] Von Bohlen und Halbach, O.; Dermietzel, R. Neurotransmitters and Neuromodulators. Handbook of Receptors and Biological Effects, 2nd Ed.; Wiley-VCH: New York, 2006, p. 107. [44] Johnson, J. W.; Kotermanski, S. E. Mechanism of action of memantine. Curr. Opin. Pharmacol. 2006, 6, 61-67. https://doi.org/10.1016/j.coph.2005.09.007. [45] Parsons, C. G.; Danysz, W.; Rammes, G. Pharmacodynamics of memantine: an update. Curr. Neuropharmacol. 2008, 6, 55-78. https://doi.org/10.2174/157015908783769671. [46] Paoletti, P.; Bellone, C.; Zhou, Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat. Rev. Neurosci. 2013, 14, 383-400. https://doi.org/10.1038/nrn3504. [47] Wang, R.; Reddy, P. H. Role of glutamate and NMDA receptors in Alzheimer's disease. J. Alzheimer's Dis. 2017, 57, 1041-1048. https://doi.org/10.3233/JAD-160763. [48] Danysz, W.; Parsons, C. G.; Jirgensons, A.; Kauss, V.; Tillner, J. Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists. Curr. Pharm. Des. 2002, 8, 835-843. https://doi.org/10.2174/1381612024607117. [49] Companys-Alemany, J.; Turcu, A. L.; Bellver-Sanchis, A.; Loza, M. I.; Brea, J. M.; Canudas, A. M.; Leiva, R.; Vázquez, S.; Pallàs, M.; Griñán-Ferré, C. A novel NMDA receptor antagonist protects against cognitive decline presented by senescent mice. Pharmaceutics 2020, 12, 284. https://doi.org/10.3390/pharmaceutics12030284. [50] Song, X.; Jensen, M. O.; Jogini, V.; Stein, R. A.; Lee, C.-H.; Mchaourab, H. S.; Shaw, D. E.; Gouaux, E. Mechanism of NMDA receptor channel block by MK-801 and memantine. Nature 2018, 556, 515-519. https://doi.org/10.1038/s41586-018-0039-9. [51] Chou, T.-H.; Epstein, M.; Michalski, K.; Fine, E.; Biggin, P. C.; Furukawa, H. Structural insights into binding of therapeutic channel blockers in NMDA receptors. Nat. Struct. Mol. Biol. 2022, 29, 507-518. https://doi.org/10.1038/s41594-022-00772-0. [52] Chou, T.-H.; Epstein, M.; Fritzemeier, R. G.; Akins, N. S.; Paladugu, S.; Ullman, E. Z.; Liotta, D. C.; Traynelis, S. F.; Furukawa, H. Molecular mechanism of ligand gating and opening of NMDA receptor. Nature 2024, 632, 209-217. https://doi.org/10.1038/s41586-024-07742-0. [53] Shteinikov, V. Y.; Tikhonova, T. B.; Korkosh, V. S.; Tikhonov, D. B. Potentiation and block of ASIC1a by memantine. Cell. Mol. Neurobiol. 2018, 38, 869-881. https://doi.org/10.1007/s10571-017-0561-6. [54] Glasgow, N. G.; Wilcox, M. R.; Johnson, J. W. Effects of Mg2+ recovery of NMDA receptors from inhibition by memantine and ketamine reveal properties of a second site. Neuropharmacology 2018, 137, 344-358. https://doi.org/10.1016/j.neuropharm.2018.05.017. [55] Wilcox, M. R.; Nigam, A.; Glasgow, N. G.; Narangoda, C.; Phillips, M. B.; Patel, D. S.; Mesbahi-Vasey, S.; Turcu, A. L.; Vazquez, S.; Kurnikova, M. G.; Johnson, J. W. Inhibition of NMDA receptors through a membrane-to-channel path. Nat. Commun. 2022, 13, 4114. https://doi.org/10.1038/s41467-022-31817-z. [56] Moriguchi, S.; Ishikuza, T.; Yahuki, Y.; Shioda, N.; Sasaki, Y.; Tagashira, H.; Yawo, H.; Yeh, J. Z.; Sakagami, H.; Narahashi, T.; Fukunaga, K. Blockade of the KATP channel Kir6.2 by memantine represents a novel mechanism relevant to Alzheimer's disease therapy. Mol. Psych. 2018, 23, 211-221. https://doi.org/10.1038/mp.2016.187. [57] Carrillo, E.; Romero, A. M.; Gonzalez, C. U.; Turcu, A. L.; Vázquez, S.; Twomey, E. C.; Jayaraman, V. Memantine inhibits calcium permeable AMPA receptors. Nat. Commun. 2025, 16, 5576. https://doi.org/10.1038/s41467-025-60543-5. [58] MacLean M. A.; Muradov, J. H.; Greene, R.; Van Hameren, G.; Clarke, D. B.; Dreier, J. P.; Okonkwo, D. O.; Friedman, A. Memantine inhibits cortical spreading depolarization and improves neurovascular function following repetitive traumatic brain injury. Sci. Adv. 2023, 9, eadj2417. https://doi.org/10.1126/sciadv.adj2417. [59] Walker, L. C.; Jucker, M. The prion principle and Alzheimer's disease. Science 2024, 385, 1278-1279. https://doi.org/10.1126/science.adq5252. [60] Ito, K.; Tatebe, T.; Suzuki, K.; Hirayama, T.; Hayakawa, M.; Kubo, H.; Tomita, T.; Makino, M. Memantine reduces the production of amyloid- peptides through modulation of amyloid precursor protein trafficking. Eur. J. Pharmacol. 2017, 798, 16-25. https://doi.org/10.1016/j.ejphar.2017.02.001. [61] Takahashi-Ito, K.; Makino, M.; Okado, K.; Tomita, T. Memantine inhibits -amyloid aggregation and disassembles preformed -amyloid aggregates. Biochem. Biophys. Res. Commun. 2017, 493, 158-163. https://doi.org/10.1016/j.bbrc.2017.09.058. [62] Jonnalagadda, S. V. R.; Gerace, A. J.; Thai, K.; Johnson, J.; Tsimenidis, K.; Jakubowski, J. M.; Shen, C.; Henderson, K. J.; Tamamis, P.; Grikas, M. Amyloid peptide scaffolds coordinate with Alzheimer's disease drugs. J. Phys. Chem. B 2020, 124, 487-503. https://doi.org/10.1021/acs.jpcb.9b10368. [63] Inoue, Y.; Ueda, M.; Masuda, T.; Misumi, Y.; Yamashita, T.; Ando, Y. Memantine, a noncompetitive N-methyl-D-aspartate receptor antagonist, attenuates cerebral amyloid angiopathy by increasing insulin-degrading enzyme expression. Mol. Neurobiol. 2019, 56, 8573-8588. https://doi.org/10.1007/s12035-019-01678-7. [64] Coombs, S. E.; Banjade, S.; Kriksunov, K.; Clemente, N.; Zhao, J.; Wang, C.; Gillilan, R. E.; Oswald, R. E. In vitro effects of (+)MK-801 (dizocilpine) and memantine on -amyloid peptides linked to Alzheimer's disease. Biochemistry 2020, 59, 4517-4522. https://doi.org/10.1021/acs.biochem.0c00813. [65] Fani, G.; Mannini, B.; Vecchi, G.; Cascella, R.; Cecchi, C.; Dobson, C. M.; Vendruscolo, M.; Chiti, F. A oligomers dysregulate calcium homeostasis by mechanosensitive activation of AMPA and NMDA receptors. ACS Chem. Neurosci. 2021, 12, 766-781. https://doi.org/10.1021/acschemneuro.0c00811. [66] Bovis, K.; Davies-Branch, M.; Day, P. J. R. Dysregulated neurotransmission and the role of viruses in Alzheimer's disease. ACS Chem. Neurosci. 2025, 16, 982-987. https://doi.org/10.1021/acschemneuro.4c00763. [67] Spasov, A. A.; Khamidova, T. V.; Bugaeva, L. I.; Morozov, I. S. Molecular-biological problems of drug design and mechanism of drug action. Adamantane derivatives: pharmacological and toxicological properties (review). Pharm. Chem. J. 2000, 34, 3-9. https://doi.org/10.1007/BF02524549. [68] Pathak, C.; Kabra, U. D. A comprehensive review of multi-target directed ligands in the treatment of Alzheimer's disease. Bioorg. Chem. 2024, 144, 107152. https://doi.org/10.1016/j.bioorg.2024.107152. [69] Koola, M. M.; Nikiforuk, A.; Pillai, A.; Parsaik, A. K. Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer's disease: critical dissection with an emphasis on kyneurinic acid and mismatch negativity. J. Geriat. Care Res. 2018, 5, 57-67. [70] Akkaya, C.; Yavuzer, S. S.; Yavuzer, H.; Erkol, G.; Bozluolcay, M.; Dincer, Y. DNA damage, DNA susceptibility to oxidation and glutathione redox status in patients with Alzheimer's disease treated with and without memantine. J. Neurol. Sci. 2017, 378, 158-162. https://doi.org/10.1016/j.jns.2017.04.051. [71] Yaghmaei, E.; Lu, H.; Ehwerhemuepha, L.; Zheng, J.; Danioko, S.; Rezaie, A.; Sajjadi, S. A.; Rakovski, C. Combined use of donepezil and memantine increases the probability of five-year survival of Alzheimer's disease patients. Commun. Med. 2024, 4, 99. https://doi.org/10.1038/s43856-024-00527-6. [72] Chen, R.; Chan, P.-T.; Chu, H.; Lin, Y.-C.; Chang, P.-C.; Chen, C.-Y.; Chou, K.-R. Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer's disease. PLoS One 2017, 12, e0183586. https://doi.org/10.1371/journal.pone.0183586. [73] Mittapelly, N.; Pandley, G.; Tulsankar, S. L.; Arfi, S.; Bhatta, R. S.; Mishra, P. R. In depth analysis of pressure-sensitive adhesive patch-assisted delivery of memantine and donepezil using physiologically based pharmacokinetic modeling and in vitro/in vivo correlations. Mol. Pharmaceutics 2018, 15, 2646-2655. https://doi.org/10.1021/acs.molpharmaceut.8b00176. [74] Kaur, A.; Nigam, K.; Srivastava, S.; Tyagi, A.; Dang, S. Memantine nanoemulsion: a new approach to treat Alzheimer's disease. J. Microencapsul. 2020, 37, 355-365. https://doi.org/10.1080/02652048.2020.1756971. [75] Radwan, R. R.; Ghaffar, A. M. A.; Ali, H. E. Gamma radiation preparation of chitosan nanoparticles for controlled delivery of memantine. J. Biomat. Appl. 2020, 34, 1150-1162. https://doi.org/10.1177/0885328219890071. [76] Vos, P. J.; Kuijt, N.; Kaya, M.; Rol, S.; Van der Maaden, K. Nanoporous microneedle arrays seamlessly connected to a drug reservoir for tunable transdermal delivery of memantine. Eur. J. Pharm. Sci. 2020, 150, 105331. https://doi.org/10.1016/j.ejps.2020.105331. [77] Pathuru, S.; Sankar, G. B.; Valluri, G. S.; Raghunadha, C. Manufacture and preparation of stabilized combined multistage compositions of memantine HCl extended release and donepezil HCl immediate release pellets. Patent WO2021 234475 A1 (2021). [78] Handa, M.; Sanap, S. N.; Bhatta, R. S.; Patil, G. P.; Palkhade, R.; Singh, D. P.; Shukla, R. Simultaneous intranasal codelivery of donepezil and memantine in a nanocolloidal carrier: optimization, pharmacokinetics, and pharmacodynamics studies. Mol. Pharmaceutics 2023, 20, 4714-4728. https://doi.org/10.1021/acs.molpharmaceut.3c00454. [79] Lee, D.; Shen, A. M.; Shah, M.; Garbuzenko, O. B.; Minko, T. In vivo evaluation of nose-to-brain delivery of liposomal donepezil, memantine, and BACE-1 siRNA for Alzheimer's disease therapy. Int. J. Mol. Sci. 2024, 25, 10357. https://doi.org/10.3390/ijms251910357. [80] Saleh, M. A.; Mohamed, J. M. M.; Ruby, J. J.; Kanthiah, S.; Alanazi, Y. F.; Mairashi, K. A.; Alshahrani, S. M.; Eladl, M. A.; Alaryani, F. S.; El-Sherbiny, M.; Menaa, F. Preparation of memantine-loaded chitosan nanocrystals: in vitro and ex vivo toxicity analysis. Crystals 2023, 13, 21. https://doi.org/10.3390/cryst13010021. [81] Kanasty, R.; Low, S.; Bhise, N.; Yang, J.; Peeke, E.; Schwarz, M.; Wright, J.; Carter, B.; Moorthy, S.; Grant, T.; DeBenedictis, B.; Bishoff, M.; Simses, C.; Bellinger, A. M. A pharmaceutical answer to nonadherence: once weekly oral memantine for Alzheimer's disease. J. Control. Release 2019, 303, 34-41. https://doi.org/10.1016/j.jconrel.2019.03.022. [82] Sánchez-López, E.; Ettcheto, M.; Egea, M. A.; Espina, M.; Cano, A.; Calpena, A. C.; Camins, A.; Carmona, N.; Silva, A. M.; Souto, E. B.; Garcia, M. L. Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization. J. Nanobiotechnol. 2018, 16, 32. https://doi.org/10.1186/s12951-018-0356-z. [83] Tezel, G.; Uluturk, S.; Recber, T.; Timur, S. S.; Nemutlu, E.; Esendagli, G.; Pinar, S. G.; Eroglu, H. Preparation and in vitro characterization of memantine HCl loaded PLGA nanoparticles for Alzheimer's disease. J. Drug Delivery Sci. Technol. 2024, 100, 106142. https://doi.org/10.1016/j.jddst.2024.106142. [84] Antonoglou, O.; Giannousi, K.; Mourdikoudis, S.; Dendrinou-Samara, C. Magnetic nanoemulsions as candidates for Alzheimer's disease dual imaging theranostics. Nanotechnology 2020, 31, 465702. https://doi.org/10.1088/1361-6528/abac35. [85] Humbert, M.; Cohen-Kaminsky, S.; Dumas, S.; Bru-Mercier, G.; Alami, M.; Brion, J.-D.; Meassaoudi, S.; Galvani, G. Novel adamantane and memantine derivatives as peripheral NMDA receptor antagonists and their preparation. Patent WO2017 017116 A1 (2017). [86] Gazova, Z.; Soukup, O.; Sepsova, V.; Siposova, K.; Drtinova, L.; Jost, P.; Spilovska, K.; Korabecny, J.; Nepovimova, E.; Fedunova, D.; Horak, M.; Kaniakova, M.; Wang, Z.-J.; Hamouda, A. K.; Kuca, K. Multi-target-directed therapeutic potential of 7-methoxyacrine-adamantylamine heterodimers in the Alzheimer's disease treatment. Biochim. Biophys. Acta 2017, 1863, 607-619. https://doi.org/10.1016/j.bbadis.2016.11.020. [87] Basagni, F.; Ortega, J. A.; Bertozzi, S. M.; Armirotti, A.; Summa, M.; Bertorelli, R.; Bartolini, M.; Mellor, I. R.; Bedeschi, M.; Bottegoni, G.; Lembo, V.; Minarini, A.; Cavalli, A.; Rosini, M. Galantamine-memantine hybrids for Alzheimer's disease: the influence of linker rigidity in biological activity and pharmacokinetic properties. Eur. J. Med. Chem. 2023, 261, 115803. https://doi.org/10.1016/j.ejmech.2023.115803. [88] Singhal, M.; Merino, V.; Rosini, M.; Cavalli, A.; Kalia, Y. N. Controlled iontophoretic delivery in vitro and in vivo of ARN14140 – A multitarget compound for Alzheimer's disease. Mol. Pharmaceutics 2019, 16, 3460-3468. https://doi.org/10.1021/acs.molpharmaceut.9b00252. [89] Kumamoto, T.; Nakajima, M.; Uga, R.; Ihayazaka, N.; Kashihara, H.; Katakawa, K.; Ishikawa, T.; Saiki, R.; Nishimura, K.; Igarashi, K. Design, synthesis, and evaluation of polyamine-memantine hybrids as NMDA channel blockers. Bioorg. Med. Chem. 2018, 26, 603-608. https://doi.org/10.1016/j.bmc.2017.12.021. [90] Takayama, H.; Yaegashi, Y.; Kitajima, M.; Han, X.; Nishimura, K.; Okuyama, S.; Igarashi, K. Design, synthesis, and biological evaluation of tricyclic heterocycle-tetraamine conjugates as potent NMDA channel blockers. Bioorg. Med. Chem. Lett. 2007, 17, 4729-4732. https://doi.org/10.1016/j.bmcl.2007.06.069. [91] Rada, M. S.; Cardona-Galeano, W.; Quintero-Saumeth, J.; Sierra, K.; Osorio, E.; Gonález-Molina, L. A.; Posada-Duque, R.; Yepes, A. F. Novel multipotent amantadine-M30D hybrids with highly selective butyrylcholinesterase inhibition and neuroprotective effects as effective anti-Alzheimer's agents. ACS Chem. Neurosci. 2022, 13, 2681-2698. https://doi.org/10.1021/acschemneuro.2c00300. [92] Naki, T.; Matshe, W. M. R.; Balogun, M. O.; Ray, S. S.; Egieyeh, S. A.; Aderibigbe, B. A. Polymer drug conjugates containing memantine, tacrine and cinnamic acid: promising nanotherapeutics for the treatment of Alzheimer's disease. J. Microencapsul. 2023, 40, 15-28. https://doi.org/10.1080/02652048.2023.2167011. [93] Araujo de Oliveira, A. P.; Colmenares, V. C. R.; Diniz, R.; Freitas, J. T. J.; Da Cruz, C. M.; Lages, E. B.; Ferreira, L. A. M.; Vieira, R. P.; Beraldo, H. Memantine-derived Schiff bases as transdermal prodrug candidates. ACS Omega 2022, 7, 11678-11687. https://doi.org/10.1021/acsomega.1c06571. [94] Kuang, W.; Liu, J.; Lin, X.; Wu, S.; Gong, J.; Yin, Q.; Wang, J. Insoluble salt of memantine with a unique fluorescence phenomenon. Mol. Pharmaceutics 2022, 19, 1389-1399. https://doi.org/10.1021/acs.molpharmaceut.1c00931. [95] Zhang, W.; Kandel, N.; Zhou, Y.; Smith, N.; Ferreira, B. C. L. B.; Pérez, M.; Claure, M. L.; Mintz, K. J.; Wang, C.; Leblanc, R. M. Drug delivery of memantine with carbon dots for Alzheimer's disease: blood-brain barrier penetration and inhibition of tau aggregation. J. Colloid Interf. Sci. 2022, 617, 20-31. https://doi.org/10.1016/j.jcis.2022.02.124. [96] Sagar, G.; Wilson, B.; Mukundan, G. K.; Divekar, K.; Jenita, J. L. Nanomedicine for treating major brain diseases: advances and future directions. Mol. Pharmaceutics 2025, 22, 4413-4434. https://doi.org/10.1021/acs.molpharmaceut.5c00277. [97] Li, Z.; Zhang, Z.; Yu, B. Unlocking the therapeutic potential of natural products for Alzheimer's disease. J. Med. Chem. 2025, 68, 2377-2402. https://doi.org/10.1021/acs.jmedchem.4c03049. [98] Pandya, K.; Roul, K.; Tripathi, A.; Belemkar, S.; Sinha, A.; Erol, M.; Kumar, D. Alzheimer's disease: a review of molecular mechanisms and therapeutic implications by targeting sirtuins, caspases, and CSK-3. ACS Chem. Neurosci. 2025, 16, 2178-2195. https://doi.org/10.1021/acschemneuro.5c00207. [99] Cacciatore, I.; Fornasari, E.; Marinelli, L.; Eusepi, P.; Ciulia, M.; Ozdemir, O.; Tatar, A.; Turkez, H.; Di Stefano, A. Memantine-derived drugs as potential antitumor agents for the treatment of glioblastoma. Eur. J. Pharm. Sci. 2017, 109, 402-411. https://doi.org/10.1016/j.ejps.2017.08.030. [100] Ning, C.; Mo, L.; Chen, X.; Tu, W.; Wu, J.; Hou, S.; Xu, J. Triptolide derivatives as potential anti-Alzheimer agents: synthesis and structure-activity relationship studies. Bioorg. Med. Chem. Lett. 2018, 28, 689-693. https://doi.org/10.1016/j.bmcl.2018.01.019. [101] Rosini, M.; Simoni, E.; Caporaso, R.; Basagni, F.; Catanzaro, M.; Abu, I. F.; Fagiani, F.; Fusco, F.; Masuzzo, S.; Albani, D.; Lanni, C.; Mellor, I. R.; Minarini, A. Merging memantine and ferulic acid to probe connections between NMDA receptors, oxidative stress and amyloid- peptide in Alzheimer's disease. Eur. J. Med. Chem. 2019, 180, 111-120. https://doi.org/10.1016/j.ejmech.2019.07.011. [102] Tencheva, A.; Liu, R.; Volkova, T. V.; Chayrov, R.; Mitrev, Y.; Štícha, M.; Li, Y.; Jiang, H.; Li, Z.; Stankova, I.; Perlovich, G. L. Synthetic analogs of memantine as neuroprotective and influenza viral inhibitors: in vitro and physicochemical studies. Amino Acids 2020, 52, 1559-1580. https://doi.org/10.1007/s00726-020-02914-4. [103] Chayrov, R.; Volkova, T.; Perlovich, G.; Zeng, L.; Li, Z.; Štícha, M.; Liu, R.; Stankova, I. Synthesis, neuroprotective effect and physicochemical studies of novel peptide and nootropic analogues of Alzheimer disease drug. Pharmaceuticals 2022, 15, 1108. https://doi.org/10.3390/ph15091108. [104] Sokolov, V. B.; Aksinenko, A. Y.; Goreva, T. V.; Epishina, T. A.; Grigor'ev, V. V.; Gabrel'yan, A. V.; Vinogradova, D. V.; Neganova, M. E.; Shevtsova, E. F.; Bachurin, S. O. Molecular design of multitarget neuroprotector 3. Synthesis and bioactivity of tetrahydrocarbazole-aminoadamantane conjugates. Russ. Chem. Bull. 2016, 65, 1354-1359. https://doi.org/10.1007/s11172-016-1461-5. [105] Sozio, P.; Cerasa, L. S.; Laserra, S.; Cacciatore, I.; Cornacchia, C.; Di Filippo, E. S.; Fulle, S.; Fontana, A.; Di Crescenzo, A.; Grilli, M.; Marchi, M.; Di Stefano, A. Memantine-sulfur containing antioxidant conjugates as potential prodrugs to improve the treatment of Alzheimer's disease. Eur. J. Pharm. Sci. 2013, 49, 187-198. https://doi.org/10.1016/j.ejps.2013.02.013. [106] Terpstra, K.; Gutiérrez, C.; Gui, K.; Mirica, L. M. Donepezil and memantine derivatives for dual-function and prodrug applications in Alzheimer's disease. ACS Chem. Neurosci. 2025, 16, 3591-3602. https://doi.org/10.1021/acschemneuro.5c00493. [107] Chen, B. K.; Le Pen, G.; Eckmier, A.; Rubinstein, G.; Jay, T. M.; Denny, C. A. Fluoroethylnormemantine, a novel derivative of memantine facilitates extinction learning without sensorimotor deficits. Int. J. Neuropsychopharmacol. 2021, 24, 519-531. https://doi.org/10.1093/ijnp/pyab007. [108] Freyssin, A.; Carles, A.; Guehairia, S.; Rubinstein, G.; Maurice, T. Fluoroethylnormemantine (FENM) shows synergistic protection in combination with a sigma-1 receptor agonist in a mouse model of Alzheimer's disease. Neuropharmacology 2024, 242, 109733. https://doi.org/10.1016/j.neuropharm.2023.109733. [109] Carles, A.; Freyssin, A.; Guehairia, S.; Reguero, T.; Vignes, M.; Hirbec, H.; Rubinstein, G.; Maurice, T. Neuroprotection by chronic administration of fluoroethylnormemantine (FENM) in mouse models of Alzheimer's disease. Alzh. Res. Therapy 2025, 17, 7. https://doi.org/10.1186/s13195-024-01648-9. [110] Turcu, A. L.; Companys-Alemany, J.; Phillips, M. B.; Patel, D. S.; Griñán-Ferré, C.; Loza, M. I.; Brea, J. M.; Pérez, B.; Soto, D.; Sureda, F. X.; Kurnikova, M. G.; Johnson, J. W.; Pallàs, M.; Vázquez, S. Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease. Eur. J. Med. Chem. 2022, 236, 114354. https://doi.org/10.1016/j.ejmech.2022.114354. [111] Wu, Y.; Pons, V.; Noël, R.; Kali, S.; Shtanko, O.; Davey, R. A.; Popoff, M. R.; Tordo, N.; Gillet, D.; Cintrat, J.-C.; Barbier, J. DABMA: A derivative of ABMA with improved broad-spectrum inhibitory activity of toxins and viruses. ACS Med. Chem. Lett. 2019, 10, 1140-1147. https://doi.org/10.1021/acsmedchemlett.9b00155. [112] Sestito, S.; Daniele, S.; Pietrobono, D.; Citi, V.; Bellusci, L.; Chiellini, G.; Calderone, V.; Martini, C.; Rapposelli, S. Memantine prodrug as a new agent for Alzheimer's disease. Sci. Rep. 2019, 9, 4612. https://doi.org/10.1038/s41598-019-40925-8. [113] Liu, Z.; Yang, S.; Jin, X.; Zhang, G.; Guo, B.; Chen, H.; Yu, P.; Sun, Y.; Zhang, Z.; Wang, Y. Synthesis and biological evaluation of memantine nitrates as a potential treatment for neurodegenerative diseases. MedChemComm 2016, 8, 135-147. https://doi.org/10.1039/c6md00509h. [114] Mak, S.; Liu, Z.; Wu, L.; Guo, B.; Luo, F.; Liu, Z.; Hu, S.; Wang, J.; Cui, G.; Sun, Y.; Wang, Y.; Zhang, G.; Han, Y.; Zhang, Z. Pharmacological characterization of anti-dementia memantine nitrate via neuroprotection and vasodilation in vitro and in vivo. ACS Chem. Neurosci. 2020, 11, 314-327. https://doi.org/10.1021/acschemneuro.9b00242. [115] Altinoz, M. A.; Elmaci, I. Targeting nitric oxide and NMDA receptor-associated pathways in treatment of high grade glial tumors. Hypotheses for nitro-memantine and nitrones. Nitric Oxide 2018, 79, 68-83. https://doi.org/10.1016/j.niox.2017.10.001. [116] Nakamura, T.; Lipton, S. A. Preventing Ca2+-mediated nitrosative stress in neurodegenerative diseases: possible pharmacological strategies. Cell Calcium 2010, 47, 190-197. https://doi.org/10.1016/j.ceca.2009.12.009. [117] Thomas, S. J.; Grossberg, G. T. Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin. Interv. Aging 2009, 4, 367-377. https://doi.org/10.2147/cia.s6666. [118] Czarnecka, K.; Chuchmacz, J.; Wójtowicz, P.; Szymanski, P. Memantine in neurological disorders – schizophrenia and depression. J. Mol. Med. (Berl) 2021, 99, 327-334. https://doi.org/10.1007/s00109-020-01982-z. [119] Hoss, S. E.; Bazoum, H. From old to new: repurposed drugs in the battle towards curing sickle cell disease. Brit. J. Haematol. 2025, 206, 795-797. https://doi.org/10.1111/bjh.19912. [120] Hu, H.; Wu, L.; Hu, X.; Wang, M.; Sun, Y.; Zhang, G.; Wang, Y.; Yi, P.; Zhang, Z. Neuroprotective and intraocular pressure lowering effects of dual-functional memantine nitrate MN-08 on the experimental models of glaucoma. Sci. Rep. 2025, 15, 23822. https://doi.org/10.1038/s41598-025-06832-x. [121] Mohyeldin, R. H.; Sharata, E. E.; Fawzy, M. A.; Attya, M. E.; Welson, N. N.; Rofaeil, R. R. Memantine abrogates testicular dysfunction induced by risperidone in rats with a potential role of ERK1/2-Nrf2-caspase-3 signaling pathway. Sci. Rep. 2025, 15, 12914. https://doi.org/10.1038/s41598-025-94760-1. [122] Pal, S. et al. Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomized, adaptive platform trial. Lancet Neurol. 2024, 23, 1097-1107. https://doi.org/10.1016/s1474-4422(24)00326-0. [123] Weaver, D. F. Alzheimer's is not a single disease. ACS Chem. Neurosci. 2025, 16, 2340-2342. https://doi.org/10.1021/acschemneuro.5c00446. [124] Pizzo, M. E. et al. Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA. Science 2025, 389, eads3204. https://doi.org/10.1126/science.ads3204. [125] Aron, L.; Ngian, Z. K.; Qiu, C.; Choi, J.; Liang, M.; Drake, D. M.; Hamplova, S. E.; Lacey, E. K.; Roche, P.; Yuan, M.; Hazaveh, S. S.; Lee, E. A.; Bennett, D. A.; Yankner, B. A. Lithium deficiency and the onset of Alzheimer's disease. Nature 2025, 645, 712-721. https://doi.org/10.1038/s41586-025-09335-x. [126] Leonard, H. L.; Nalls, M. A.; Day-Williams, A.; Esmaeeli, S.; Jarreau, P.; Bandres-Ciga, S.; Heutink, P.; Sardi, S. P.; Singleton, A. B. Open science in precision medicine for neurodegenerative diseases. Nat. Rev. Drug Discov. 2024, 23, 233-234. https://doi.org/10.1038/d41573-024-00017-3. [127] Shvetcov, A.; Johnson, E. C. B.; Winchester, L. M.; Walker, K. A.; Wilkins, H. M.; Thompson, T. G.; Rothstein, J. D.; Krish, V.; Imam, F. B.; The Global Neurodegeneration Proteomics Consortium (GNPC); Burns, J. M.; Swerdlow, R. H.; Slawson, C.; Finney, C. A. APOE 4 carries share immune-related proteomic changes across neurodegenerative diseases. Nat. Med. 2025, 31, 2590-2601. https://doi.org/10.1038/s41591-025-03835-z.